| Document Date: 2011-09-05 09:50:55
Open Document File Size: 2,17 MBShare Result on Facebook
City Strasbourg / Adelaide / / Company Thompson Pharma / Pfizer / Bayer / Hoosier Oncology Group / BNC105 / Merck Serono / BNO69 Immune Disease Central Inhibitors Multiple Sclerosis / regarding Bionomics’ development candidates BNC105 / / Continent Europe / / Country United States / Australia / / Currency USD / / Event FDA Phase / Business Partnership / / IndustryTerm tumour imaging / acquired businesses and technologies / competitors products / technology platforms / / MedicalCondition Cancer / burn / GABA-A agonists Epilepsy / clear cell renal cell carcinoma / tumour / metastatic disease / cell cancer / mesothelioma / Anxiety/ Depression / renal cancer / Multiple Sclerosis / Anxiety/Depression / Stable disease / Epilepsy / renal cell carcinoma / Kidney cancer / kidney cancers / / MedicalTreatment radiation treatment / chemotherapy / / Organization Federal Drug Administration / / Person Deborah Rathjen / / Position CEO & Managing Director / Director 24 March / Therapeutic Area Australia USA Head / / Product cisplatin / Nexavar / Avastin / Sutent / Kv1 / Sutent® (Pfizer) / BNC210 / US47M / Commercial Opportunity Afinitor® / Federal Drug / Investigational New Drug / Avastin® June / / Technology radiation / drug discovery / Biotechnology / chemotherapy / /
SocialTag |
The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010